GFAP and Parkinson disease: Higher expression levels of GFAP have been shown in post-mortem MSA brain tissue compared to PD and healthy controls (HC) [15], while first data also show a detectable upregulation of GFAP in CSF and plasma in multiple neurodegenerative diseases, including atypical parkinsonian syndromes [16].